Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Paraganglioma × vandetanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 8 Neoplasms 4 Lung Neoplasms 4 Glioma 4 Neoplasm Metastasis 3 Glioblastoma 3 Colorectal Neoplasms 3 Brain Neoplasms 3 Pancreatic Neoplasms 2 Head and Neck Neoplasms 2 Gliosarcoma 2 Esophageal Neoplasms 2 Carcinoma, Medullary 2 Breast Neoplasms 2 Adenocarcinoma 2 Waldenstrom Macroglobulinemia 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sezary Syndrome 1 Salivary Gland Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pheochromocytoma 1

Interventions

Everolimus 2 vandetanib 1 spartalizumab 1 gallium Ga 68 dotatate 1 fludarabine phosphate 1 cixutumumab 1 Specimen Handling 1 Salts 1 Octreotide 1 Magnetic Resonance Spectroscopy 1 Interleukin-13 1 Fluorodeoxyglucose F18 1 Cyclophosphamide 1 Biopsy 1 Acetates 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡